BridgeMD
New treatment option for Acute Heart Failure
Official title Infusion of Furosemide to Improve Diuretic Efficiency in Acute Heart Failure
ClinicalTrials.gov ID: NCT07577596
What this study is testing
What is Intravenous furosemide continuous infusion?
Intravenous furosemide continuous infusion is an investigational medicine, given as an once-daily infusion into a vein, being studied as a potential treatment for acute heart failure.
Also referred to as Furosemide infusion.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Acute heart failure is a condition where the heart suddenly cannot pump blood well enough for the body's needs. Many people admitted to the hospital with acute heart failure have too much fluid in the body.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Clinical diagnosis of acute heart failure with volume overload
- At least 1 sign of volume overload
- Anticipated intravenous furosemide treatment for at least 3 days
- Age 18 years or older
You likely can't join if
- Shock
- Patient requiring treatment with inotropes or vasopressors
- Current or planned use of renal replacement therapy or ultrafiltration
- Patient with a renal transplant
- Patients who are pregnant or breastfeeding
- Severe hypokalaemia, defined as potassium less than 2.5 mmol/L, or severe hyponatremia, defined as sodium less than 125 mmol/L
See the full eligibility criteria
- Clinical diagnosis of acute heart failure with volume overload
- At least 1 sign of volume overload
- Anticipated intravenous furosemide treatment for at least 3 days
- Age 18 years or older
- Shock
- Patient requiring treatment with inotropes or vasopressors
- Current or planned use of renal replacement therapy or ultrafiltration
- Patient with a renal transplant
- Patients who are pregnant or breastfeeding
- Severe hypokalaemia, defined as potassium less than 2.5 mmol/L, or severe hyponatremia, defined as sodium less than 125 mmol/L
- Allergy to furosemide and its components
The study team makes the final eligibility decision.
Where it's taking place
- Randers, Denmark
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Randers, Denmark. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.